Europe Inhalers for Chronic Obstructive Pulmonary Disorder Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Inhalers for Chronic Obstructive Pulmonary Disorder Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Metered-Dose Inhalers (MDI's) Market Performance (Volume)
  • 2.1.2 Dry Powder Inhalers (DPI's) Market Performance (Volume)
  • 2.1.3 Soft Mist Inhalers (SMI's) Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Metered-Dose Inhalers (MDI's) Market Performance (Value)
  • 2.1.2 Dry Powder Inhalers (DPI's) Market Performance (Value)
  • 2.1.3 Soft Mist Inhalers (SMI's) Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 GOLD 1： FEV1 ≥ 80% Market Performance (Volume)
  • 3.1.2 GOLD 2： 50% ≤ FEV1 < 80% Market Performance (Volume)
  • 3.1.3 GOLD 3： 30% ≤ FEV1 < 50% Market Performance (Volume)
  • 3.1.4 GOLD 4： FEV1 < 30% Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 AstraZeneca
  • 4.1.1 AstraZeneca Profiles
  • 4.1.2 AstraZeneca Product Information
  • 4.1.3 AstraZeneca Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.1.4 AstraZeneca Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.2 Boehringer Ingelheim
  • 4.2.1 Boehringer Ingelheim Profiles
  • 4.2.2 Boehringer Ingelheim Product Information
  • 4.2.3 Boehringer Ingelheim Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.2.4 Boehringer Ingelheim Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.3 GSK
  • 4.3.1 GSK Profiles
  • 4.3.2 GSK Product Information
  • 4.3.3 GSK Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.3.4 GSK Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.4 Novartis
  • 4.4.1 Novartis Profiles
  • 4.4.2 Novartis Product Information
  • 4.4.3 Novartis Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.4.4 Novartis Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.5 Teva Pharmaceuticals
  • 4.5.1 Teva Pharmaceuticals Profiles
  • 4.5.2 Teva Pharmaceuticals Product Information
  • 4.5.3 Teva Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.5.4 Teva Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.6 Ache Laboratorios Farmaceuticos
  • 4.6.1 Ache Laboratorios Farmaceuticos Profiles
  • 4.6.2 Ache Laboratorios Farmaceuticos Product Information
  • 4.6.3 Ache Laboratorios Farmaceuticos Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.6.4 Ache Laboratorios Farmaceuticos Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.7 Almirall
  • 4.7.1 Almirall Profiles
  • 4.7.2 Almirall Product Information
  • 4.7.3 Almirall Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.7.4 Almirall Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.8 Aquinox Pharmaceuticals
  • 4.8.1 Aquinox Pharmaceuticals Profiles
  • 4.8.2 Aquinox Pharmaceuticals Product Information
  • 4.8.3 Aquinox Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.8.4 Aquinox Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.9 Ario Pharma
  • 4.9.1 Ario Pharma Profiles
  • 4.9.2 Ario Pharma Product Information
  • 4.9.3 Ario Pharma Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.9.4 Ario Pharma Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.10 Asmacure
  • 4.10.1 Asmacure Profiles
  • 4.10.2 Asmacure Product Information
  • 4.10.3 Asmacure Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
  • 4.10.4 Asmacure Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
• 4.11 Astellas Pharma
• 4.12 BioMarck Pharmaceuticals
• 4.13 GSK

5 Market Performance for Manufacturers

• 5.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Market Performance (Sales Point)

• 7.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 GOLD 1： FEV1 ≥ 80% Industry
• 11.2 GOLD 2： 50% ≤ FEV1 < 80% Industry
• 11.3 GOLD 3： 30% ≤ FEV1 < 50% Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Metered-Dose Inhalers (MDI's) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Dry Powder Inhalers (DPI's) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Soft Mist Inhalers (SMI's) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 GOLD 1： FEV1 ≥ 80% Sales and and Growth Rate 2019-2024
  • 12.4.3 GOLD 2： 50% ≤ FEV1 < 80% Sales and and Growth Rate 2019-2024
  • 12.4.4 GOLD 3： 30% ≤ FEV1 < 50% Sales and and Growth Rate 2019-2024
  • 12.4.5 GOLD 4： FEV1 < 30% Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Gross Profit Trend 2019-2024

13 Conclusion